

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

August 25, 2026

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled ***"Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)"***.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)

Bengaluru, Karnataka, India, August 25, 2026

Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), received marketing approval for its pegfilgrastim biosimilar (“Product”) from Japan’s Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta®, is developed and manufactured by Biocon Biologics Ltd, parent entity of Biocon Biologics UK PLC (Biocon Biologics Ltd and Biocon Biologics UK PLC shall be collectively referred to as “Biocon”), with Global Regulatory Partners Japan serving as the Marketing Authorization Holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the Product in Japan.

This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally.

– Company Spokesperson

Neulasta® is a registered trademark of Amgen Inc.